Lundbeck and OEP Philippines, Inc. partner with RHEA Generics
More and more global pharmaceutical companies are joining the RHEA Generics bandwagon, adhering to the mission of providing Filipinos access too world-class quality medicines at very affordable prices.
The latest pharmaceutical experts to partner with RHEA Generics are Lundbeck of Denmark and OEP Philippines, Inc. the largest subsidiary of Orient Europharma Taiwan.
Lundbeck is Denmark’s leading researcher and manufacturer of pharmaceuticals for the treatment of disorders in the central nervous system including depression, schizophrenia, and insomnia.
This partnership is relevant as the Philippines recently passed RA 11036, aka the Mental Health Act. According to the Department of Health (DOH), 5.3% of Filipinos are affected by depressive disorders. During these times of COVID-19, that number may rapidly increase. Under Lundbeck, RHEA Generics is launching RHEA Escitalopram (Innovator: Lexapro) for the treatment of depressive episodes, panic, anxiety, and obsessive-compulsive disorders.
OEP Philippines specializes in respiratory disorders such as chronic obstructive pulmonary disease (COPD). The DOH identifies COPD as one of the leading diseases that causes mortality in the Philippines. With OEP Philippines, RHEA Generics has partnered with RHEA Doxofylline (Innovator: Ansimar) for the treatment of COPD, bronchial asthma and other pulmonary disorders.
These two world-class companies will further widen the RHEA Generics portfolio of much needed high-quality prescription medicines and help contribute to health and wellness in the Philippines.
